Biorepository & Tissue Analysis Shared Resource

生物储存库和组织分析共享资源：摘要 Hollings癌症中心（HCC）生物储存库和组织分析（BTA）共享资源提供了 鳄鱼与访问精心收集和注释的人类标本，以及先进的人类和 动物组织分析需要最先进的仪器和专业知识。共享资源COM- 提供多种综合服务，如生物标本和数据存储库;定制和随时可用， 组织微阵列; RNA和DNA提取;研究病理学服务，包括组织学分析， 固定、冷冻和染色的组织;以及实验结果分析。BTA与Lipidomics合作 共享资源，介绍空间分析和成像蛋白质，脂质和甘氨酸的新技术， 在病人的肿瘤组织中。通过将组织病理学与脂质、糖和蛋白质的表征联系起来， 在临床感兴趣的组织中表达，BTA为HCC研究人员提供了革命性的机会， 莫尔组织分析，并确定以前未认识到的治疗途径。 自2013年以来，BTA已从实体瘤患者中收集了26，500多份癌症相关生物标本。 肿瘤和血液恶性肿瘤，所有这些都被注释并与临床数据相关联。值得注意的是， BTA的真正意义在于它能够定制标本的累积，以满足HCC研究者的特定需求。Cur- 目前，25%的BTA组织供体是非裔美国人患者，他们在生物学中的代表性通常不足， 在癌症研究中。在目前的资助期间，BTA支持了49项研究 总部合同委员会调查员，导致30份出版物和20份获得资助的赠款申请。BTA已经做出了影响力 促进HCC癌症研究的贡献，包括从服务不足的患者中鉴定标本 具有海岛血统的患者，并使用MALDI成像研究can- cer.除了为越来越多的HCC研究者提供服务外，BTA还为主要的国家生物资源提供了贡献。 存储工作，包括NCI资助的患者衍生异种移植物（PDX）存储库，NCI资助的Coop- 美国国防部资助的多中心NCORP Early Onset Repository.在史蒂文·L.卡罗尔，医学博士，博士，常染色体基因组学专家， Nant肿瘤易感性综合征神经纤维瘤病1型，BTA已成为一个种族丰富， 与肿瘤组织生物储存库相比，它是肝癌研究人员的重要科学资源。 在将基础生物学发现与人类癌症的预防、临床诊断和治疗联系起来方面取得了进展。

BIOREPOSITORY & TISSUE ANALYSIS SHARED RESOURCE: SUMMARY The Hollings Cancer Center (HCC) Biorepository & Tissue Analysis (BTA) Shared Resource provides investi- gators with access to meticulously collected and annotated human specimens as well as advanced human and animal tissue analyses that require state-of-the-art instrumentation and expertise. The shared resource com- prises several integrated services such as a biospecimen and data repository; customized and readily availa- ble tissue microarrays; RNA and DNA extractions; research pathology services, including histologic analysis of fixed, frozen, and stained tissues; and analysis of experimental results. The BTA partners with the Lipidomics Shared Resource to introduce novel technologies for spatially profiling and imaging proteins, lipids, and gly- cans in patient tumor tissues. By linking histopathology to the characterization of lipid, sugar, and protein ex- pression in tissues of clinical interest, the BTA opens the opportunity for HCC investigators to revolutionize tu- mor tissue analysis and identify previously unrecognized therapeutic avenues. Since 2013, the BTA has collected more than 26,500 cancer-associated biospecimens from patients with solid tumors and hematological malignancies, all of which are annotated and linked to clinical data. A notable fea- ture of the BTA is its ability to tailor the accrual of specimens to meet specific needs of HCC investigators. Cur- rently, 25% of BTA tissue donors are African American patients, who are typically underrepresented in biore- positories and in cancer research. During the current funding period, the BTA supported the research of 49 HCC investigators, resulting in 30 publications and 20 funded grant applications. The BTA has made impactful contributions to advance cancer research at HCC, including the identification of specimens from underserved patients with Sea Island ancestry and the use of MALDI imaging to study protein glycosylation patterns in can- cer. In addition to serving a growing group of HCC investigators, the BTA contributes to major national biore- pository efforts, including the NCI-funded Patient-Derived Xenograft (PDX) Repository, the NCI-funded Coop- erative Human Tissue Network, and the DOD-funded multi-center NCORP Racially and Ethnically Diverse Early Onset Repository. Under the leadership of Steven L. Carroll, MD, PhD, an expert in the autosomal domi- nant tumor susceptibility syndrome neurofibromatosis type 1, the BTA has become an ethnically rich and di- verse tumor tissue biorepository that serves as an important scientific resource for HCC investigators inter- ested in linking basic biology findings to the prevention, clinical diagnosis, and treatment of human cancer.